Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1607
https://www.valueinhealthjournal.com/article/S1098-3015(16)01675-2/fulltext
Section Title :
Cancer - Cost Studies
Section Order :
328
First Page :
A153
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01675-2&doi=10.1016/j.jval.2016.03.1607